Funder
National Key R&D Program of China
Beijing-Tianjin-Hebei Basic Research Cooperation Project
Tianjin Municipal Commission of Health and Wellness Project
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209
2. Prasoppokakorn T, Pitisuttithum P, Treeprasertsuk S. Pharmacological therapeutics: current trends for metabolic dysfunction-associated fatty liver disease (MAFLD). J Clin Transl Hepatol. 2021;9(6):939–946
3. Le P, Chaitoff A, Rothberg MB, McCullough A, Gupta NM, Alkhouri N. Population-based trends in prevalence of nonalcoholic fatty liver disease in US adults with type 2 diabetes. Clin Gastroenterol Hepatol. 2019;17(11):2377–2378
4. Lin H, Zhang X, Li G, Wong GL, Wong VW. Epidemiology and clinical outcomes of metabolic (dysfunction)-associated fatty liver disease. J Clin Transl Hepatol. 2021;9(6):972–982
5. Chang Y, Cho YK, Cho J, Jung HS, Yun KE, Ahn J, et al. Alcoholic and nonalcoholic fatty liver disease and liver-related mortality: a cohort study. Am J Gastroenterol. 2019;114(4):620–629
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献